A compound of formula wherein R 1 is selected from the group consisting of hydrogen, fluoro, chloro, fluorinated C 1-4 alkyl and fluorinated C 1-4 alkoxy; R 2 is selected from the group consisting of hydrogen, chloro, bromo, C 1 - 4 alkyl, fluorinated C 1-4 alkyl and fluorinated C 1-4 alkoxy; provided that when R 2 is other than hydrogen, then is selected from the group consisting of wherein R 3 is selected from the group consisting of hydrogen, chloro, cyano, C 1-4 alkyl, fluorinated C 1-4 alkyl, C 1-4 alkoxy, fluorinated C 1-4 alkoxy, -O-(CH 2) 2 -OH, -O-CH 2 -CO 2 H,,-O-(CH 2) 2 -O-(C 1-4 4alkyl), -O-CH 2 -(fluorinated C 1-2 alkyl), -O-(CH 2) 2 -NR A R B and -NR A R B; wherein R A and R B are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; alternatively R A and R B are taken together with the nitrogen atom to which they are bound to form a ring structure selected form the group consisting of pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl-piperidin-1-yl, 4-methyl-piperazin-1-yl and morpholin-4-yl; Q is a ring structure selected from the group consisting of formulas (a) through (h) (a) (b) wherein R 5 is C 1-4 alkyl; R 6 is selected from the group consisting of C 1-4 alkyl and fluorinated C 1-4 alkyl; and R 7 is selected from the group consisting of hydrogen, chloro, fluoro, cyano, C 1-4 alkyl and C 1-4 alkoxy; (c) wherein R 8 and R 9 are each independently selected from the group consisting of C 1-4 alkyl; (d) wherein R 10 is C 1-4 alkyl; and R 11 is selected from the group consisting of hydrogen and cyano; (e) wherein R 12 and R 13 are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; (f) wherein R 14 is C 1-4 alkyl; (g) wherein R 15 is C 1-4 alkyl; and R 16 is selected from the group consisting of hydrogen, chloro and bromo; and (h) wherein R 17 is C 1-4 alkyl; or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. R 1 is selected from the group consisting of hydrogen, fluoro, chloro, fluorinated C 1-4 alkyl and fluorinated C 1-4 alkoxy; R 2 is selected from the group consisting of hydrogen, chloro, bromo, C 1 - 4 alkyl, fluorinated C 1-4 alkyl and fluorinated C 1-4 alkoxy; provided that when R 2 is other than hydrogen, then is selected from the group consisting of wherein R 3 is selected from the group consisting of hydrogen, chloro, cyano, C 1-4 alkyl, fluorinated C 1-4 alkyl, C 1-4 alkoxy, fluorinated C 1-4 alkoxy, -O-(CH 2) 2 -OH, -O-CH 2 -CO 2 H,,-O-(CH 2) 2 -O-(C 1-4 4alkyl), -O-CH 2 -(fluorinated C 1-2 alkyl), -O-(CH 2) 2 -NR A R B and -NR A R B; wherein R A and R B are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; alternatively R A and R B are taken together with the nitrogen atom to which they are bound to form a ring structure selected form the group consisting of pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl-piperidin-1-yl, 4-methyl-piperazin-1-yl and morpholin-4-yl; Q is a ring structure selected from the group consisting of formulas (a) through (h) (a) (b) (a) (b) wherein R 5 is C 1-4 alkyl; R 6 is selected from the group consisting of C 1-4 alkyl and fluorinated C 1-4 alkyl; and R 7 is selected from the group consisting of hydrogen, chloro, fluoro, cyano, C 1-4 alkyl and C 1-4 alkoxy; (c) (c) wherein R 8 and R 9 are each independently selected from the group consisting of C 1-4 alkyl; (d) (d) wherein R 10 is C 1-4 alkyl; and R 11 is selected from the group consisting of hydrogen and cyano; (e) (e) wherein R 12 and R 13 are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; (f) wherein R 14 is C 1-4 alkyl; (g) (f) wherein R 14 is C 1-4 alkyl; (g) wherein R 15 is C 1-4 alkyl; and R 16 is selected from the group consisting of hydrogen, chloro and bromo; and (h) wherein R 17 is C 1-4 alkyl; or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. (h) wherein R 17 is C 1-4 alkyl; or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.